6533b7d7fe1ef96bd1267aee

RESEARCH PRODUCT

Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice

Andreas TiedeJames W. IronsideMariana CanaroGiovanni Di MinnoCarlo Federico PernoLutz GürtlerDavid Navarro

subject

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyTime FactorsLong term treatmentBlood transfusionmedicine.medical_treatmentTreatment outcomeEditorials and PerspectivesHemophilia AHemorrhagic DisordersHemorrhagic disorderhemic and lymphatic diseasesBlood-Borne PathogensmedicineHumansBlood TransfusionPathogenClotting factorbusiness.industryHematologyRecombinant ProteinsTreatment OutcomeCurrent practiceImmunologybusiness

description

Hemophilia defines a group of hereditary bleeding disorders: hemophilia A (deficiency of Factor VIII, FVIII), hemophilia B (deficiency of FIX), and para-hemophilia (deficiency of FV). These result from mutations in clotting factor genes. As in the large majority of bleeding disorders ([Table 1][1

yearjournalcountryeditionlanguage
2013-10-01
10.3324/haematol.2013.084145http://hdl.handle.net/11588/597280